Rice Hall James & Associates Has Increased Keryx Biopharmaceuticals (KERX) Stake; Last Week Oaktree Capital Group (OAK) Analysts

November 15, 2017 - By Ellis Scott

Rice Hall James & Associates Llc increased Keryx Biopharmaceuticals Inc. (KERX) stake by 24.34% reported in 2017Q2 SEC filing. Rice Hall James & Associates Llc acquired 326,285 shares as Keryx Biopharmaceuticals Inc. (KERX)’s stock rose 24.11%. The Rice Hall James & Associates Llc holds 1.67 million shares with $12.05M value, up from 1.34 million last quarter. Keryx Biopharmaceuticals Inc. now has $562.88 million valuation. The stock declined 0.84% or $0.04 reaching $4.74 on the news. About 58,858 shares traded. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since November 15, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.

Among 9 analysts covering Oaktree Capital Group (NYSE:OAK), 2 have Buy rating, 1 Sell and 6 Hold. Therefore 22% are positive. Oaktree Capital Group had 26 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Bank of America given on Friday, December 16. Keefe Bruyette & Woods maintained Oaktree Capital Group LLC (NYSE:OAK) rating on Wednesday, September 20. Keefe Bruyette & Woods has “Buy” rating and $53.0 target. Goldman Sachs downgraded the stock to “Hold” rating in Friday, July 28 report. The rating was initiated by Goldman Sachs with “Conviction Buy” on Tuesday, August 11. The stock has “Buy” rating by Deutsche Bank on Friday, January 8. The stock of Oaktree Capital Group LLC (NYSE:OAK) has “Hold” rating given on Tuesday, December 20 by Deutsche Bank. On Tuesday, December 6 the stock rating was initiated by Oppenheimer with “Perform”. Barclays Capital downgraded the shares of OAK in report on Thursday, October 13 to “Underweight” rating. Oppenheimer maintained the shares of OAK in report on Thursday, July 27 with “Hold” rating. Deutsche Bank maintained Oaktree Capital Group LLC (NYSE:OAK) rating on Friday, March 11. Deutsche Bank has “Buy” rating and $53 target. See Oaktree Capital Group LLC (NYSE:OAK) latest ratings:

20/09/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $53.0 Maintain
11/08/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $53.0000 Maintain
08/08/2017 Broker: Morgan Stanley Rating: Outperform Old Target: $54 New Target: $55 Maintain
28/07/2017 Broker: Goldman Sachs Rating: Hold New Target: $49.0000 Downgrade
27/07/2017 Broker: Oppenheimer Rating: Hold Maintain
18/07/2017 Broker: Oppenheimer Rating: Hold Maintain
29/06/2017 Broker: Oppenheimer Rating: Hold Maintain
28/06/2017 Broker: Jefferies Rating: Hold New Target: $49 Initiates Coverage On
29/05/2017 Broker: Keefe Bruyette & Woods Rating: Buy New Target: $53.0000 Maintain

Investors sentiment decreased to 1.23 in 2017 Q2. Its down 0.17, from 1.4 in 2017Q1. It fall, as 17 investors sold Oaktree Capital Group LLC shares while 45 reduced holdings. 22 funds opened positions while 54 raised stakes. 33.59 million shares or 2.00% more from 32.94 million shares in 2017Q1 were reported. Deutsche Natl Bank Ag holds 277,808 shares or 0.01% of its portfolio. Glenmede Trust Na accumulated 0% or 2,200 shares. Financial Architects invested in 0.03% or 4,147 shares. 2.93M are held by Invesco Ltd. Moreover, Thornburg Investment Management has 0.25% invested in Oaktree Capital Group LLC (NYSE:OAK) for 718,459 shares. Lazard Asset Management Limited Liability owns 4,000 shares. 5,277 were reported by Envestnet Asset Mngmt. Webster Comml Bank N A stated it has 724 shares. Natl Invest Svcs Inc Wi holds 2.24% or 45,768 shares in its portfolio. Stifel Corp reported 163,873 shares or 0.03% of all its holdings. Renaissance Techs Limited Liability Com accumulated 237,370 shares. Amg Natl Tru Savings Bank holds 60,115 shares. Fmr Llc stated it has 0.02% in Oaktree Capital Group LLC (NYSE:OAK). Quinn Opportunity Prns Limited Liability Co has invested 1.02% of its portfolio in Oaktree Capital Group LLC (NYSE:OAK). Moreover, Cambridge Inv Research Advsrs has 0.01% invested in Oaktree Capital Group LLC (NYSE:OAK).

About 6,492 shares traded. Oaktree Capital Group LLC (NYSE:OAK) has risen 0.83% since November 15, 2016 and is uptrending. It has underperformed by 15.87% the S&P500.

Oaktree Capital Group, LLC is an investment manager specializing in alternative investments. The company has market cap of $6.60 billion. The Firm operates through investment management segment, which consists of the investment management services that the Company provides to its clients. It has a 9.71 P/E ratio. The Firm manages investments in a range of strategies within approximately six asset classes, which include corporate debt, convertible securities, distressed debt, control investing, real estate and listed equities.

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 36 analyst reports since July 23, 2015 according to SRatingsIntel. Maxim Group maintained Keryx Biopharmaceuticals (NASDAQ:KERX) rating on Thursday, February 25. Maxim Group has “Buy” rating and $5 target. Raymond James initiated Keryx Biopharmaceuticals (NASDAQ:KERX) on Wednesday, September 9 with “Market Perform” rating. Ladenburg Thalmann maintained Keryx Biopharmaceuticals (NASDAQ:KERX) on Tuesday, August 2 with “Buy” rating. The rating was maintained by Maxim Group on Thursday, July 27 with “Buy”. The rating was maintained by Raymond James with “Outperform” on Tuesday, August 2. TH Capital downgraded the shares of KERX in report on Monday, August 10 to “Buy” rating. On Tuesday, August 2 the stock rating was downgraded by Stifel Nicolaus to “Hold”. The company was downgraded on Thursday, July 23 by Cowen & Co. The firm has “Hold” rating given on Thursday, July 27 by Cowen & Co. As per Monday, August 10, the company rating was downgraded by Roth Capital.

Investors sentiment increased to 1.97 in 2017 Q2. Its up 0.66, from 1.31 in 2017Q1. It improved, as 11 investors sold KERX shares while 18 reduced holdings. 18 funds opened positions while 39 raised stakes. 76.46 million shares or 15.57% more from 66.16 million shares in 2017Q1 were reported. Abrams Cap Mgmt LP invested in 1.64% or 5.72M shares. Intl Grp invested in 0% or 50,742 shares. Moors Cabot Incorporated invested in 10,000 shares or 0.01% of the stock. Voya Investment Management Ltd Liability Co stated it has 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Da Davidson accumulated 2,700 shares or 0% of the stock. Vanguard Grp invested in 0% or 7.20 million shares. Marco Investment Mgmt has 45,350 shares. Morgan Stanley has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Wolverine Asset Mngmt reported 19,000 shares or 0% of all its holdings. First Republic Inv Mngmt has 21,832 shares. State Street Corporation stated it has 3.13 million shares. Citadel Advsr Limited Liability Corp holds 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 108,115 shares. Rhenman & Asset Mngmt reported 425,111 shares. Clearbridge Ltd Limited Liability Company stated it has 1.47M shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: